JP2009137975A5 - - Google Patents

Download PDF

Info

Publication number
JP2009137975A5
JP2009137975A5 JP2008327022A JP2008327022A JP2009137975A5 JP 2009137975 A5 JP2009137975 A5 JP 2009137975A5 JP 2008327022 A JP2008327022 A JP 2008327022A JP 2008327022 A JP2008327022 A JP 2008327022A JP 2009137975 A5 JP2009137975 A5 JP 2009137975A5
Authority
JP
Japan
Prior art keywords
methylerythromycin
solvate
solvent
tetrahydrofuran
carbomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008327022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009137975A (ja
JP5190350B2 (ja
Filing date
Publication date
Priority claimed from US08/785,623 external-priority patent/US5945405A/en
Application filed filed Critical
Publication of JP2009137975A publication Critical patent/JP2009137975A/ja
Publication of JP2009137975A5 publication Critical patent/JP2009137975A5/ja
Application granted granted Critical
Publication of JP5190350B2 publication Critical patent/JP5190350B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2008327022A 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0 Expired - Lifetime JP5190350B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin
US08/785,623 1997-01-17

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003311358A Division JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0

Publications (3)

Publication Number Publication Date
JP2009137975A JP2009137975A (ja) 2009-06-25
JP2009137975A5 true JP2009137975A5 (https=) 2011-10-13
JP5190350B2 JP5190350B2 (ja) 2013-04-24

Family

ID=25136084

Family Applications (3)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0
JP2008327022A Expired - Lifetime JP5190350B2 (ja) 1997-01-17 2008-12-24 クラリスロマイシンの結晶形態0

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP53437298A Expired - Lifetime JP4058114B2 (ja) 1997-01-17 1997-12-19 クラリスロマイシンの結晶形態0
JP2003311358A Withdrawn JP2004075689A (ja) 1997-01-17 2003-09-03 クラリスロマイシンの結晶形態0

Country Status (18)

Country Link
US (1) US5945405A (https=)
EP (1) EP1077988A1 (https=)
JP (3) JP4058114B2 (https=)
KR (1) KR100567149B1 (https=)
CN (1) CN1174991C (https=)
AR (3) AR011077A1 (https=)
AU (1) AU735598B2 (https=)
BR (1) BR9714287A (https=)
CA (4) CA2277274C (https=)
CZ (1) CZ297433B6 (https=)
DE (1) DE97951771T1 (https=)
ES (1) ES2173058T1 (https=)
IL (1) IL130255A0 (https=)
NZ (1) NZ336073A (https=)
TR (1) TR199901578T2 (https=)
TW (1) TW574224B (https=)
WO (1) WO1998031699A1 (https=)
ZA (1) ZA98116B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
WO2001044262A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
AU2261901A (en) 2000-01-11 2001-07-24 Teva Pharma Processes for preparing clarithromycin polymorphs
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
RU2230748C2 (ru) * 2000-03-15 2004-06-20 Ханми Фарм. Ко., Лтд. Способ получения кларитромицина в виде кристаллов формы ii
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
ES2323264T3 (es) * 2001-08-01 2009-07-10 Novartis Ag Composicion para enmascaramiento del sabor.
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
ATE534373T1 (de) 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8067399B2 (en) 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
CN101426475A (zh) * 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
US20090054634A1 (en) * 2007-08-09 2009-02-26 Vinod Kumar Kansal Process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) * 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシンa誘導体
US4670549A (en) * 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
EP0260938B1 (en) * 1986-09-18 1992-12-09 Taisho Pharmaceutical Co. Ltd Erythromycin a derivatives and method for preparing the same
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンa誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンa誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンaオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
DE69730138T2 (de) * 1996-07-29 2005-03-03 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Similar Documents

Publication Publication Date Title
JP2009137975A5 (https=)
JP2004075689A5 (https=)
CN1297564C (zh) 4″-取代-9-脱氧-9a-氮杂-9a-高红霉素A衍生物的制备方法
AU2015342444B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
DE97951771T1 (de) Kristall-form 0 von clarithromycin
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
CN1259955A (zh) C-4"-取代的大环内酯衍生物
CN107501369B (zh) 一种胞苷衍生物的制备方法及其应用
US10807978B2 (en) Process for preparation of palbociclib
CN1443168A (zh) 纯晶形的5-氯-3-(4-甲磺酰基苯基)-6′-甲基-[2,3′]联吡啶及其合成方法
WO2016107289A1 (zh) 制备索非布韦晶型6的方法
WO2018000250A1 (zh) 依鲁替尼新晶型及其制备方法
JP2022060192A5 (https=)
CN101277694B (zh) 盐酸伊立替康的新晶形
CN1178951C (zh) 新型红霉素衍生物,其制法及其作为药物的应用
CN105985349A (zh) 七元环小檗碱类似物及其药物组合物、制备方法和用途
CN1351607A (zh) 大环内酯抗生素的新晶形
JP2020524707A (ja) 塩酸メフパリブの多形体およびその製造方法と使用
TWI656116B (zh) Crystal form of 9-aminomethyl substituted tetracycline compound and preparation method thereof
AU2014352372A1 (en) Taxane compound, and preparation method and use thereof
JP6533794B2 (ja) タキサン化合物、その調製方法およびその使用
US8349863B2 (en) Crystalline polymorphic form of a camptothecin analogue
CN112225730B (zh) 一种稠环化合物的晶型、其组合物、制备方法及其应用
CN1239966A (zh) 新的红霉素衍生物,其制备方法及其作为药物的用途
CN1798755A (zh) O-烷基大环内酯和氮杂内酯衍生物和制备这些化合物的区域选择性方法